Moffitt Cancer Center: Clinical Trial 20349

RESEARCH

Call Today

1-888-663-3488

Moffitt Notice of Blackbaud Data Incident. Learn More

Facebook

Twitter

Linkedin

Pinterest

Email

Clinical Trials Search

Back to Search Results

Clinical Trial 20349

Cancer Type: Breast
Study Type: Treatment
NCT#: NCT04024436

Phase: Phase II
Prinicipal Investigator: Aixa Soyano Muller

Call 813-745-6100
or 1-800-679-0775 Learn More

Overview

Study Title

A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications

Summary

The purpose of this open-label, nonrandomized, Phase 2 study is to evaluate the efficacy and safety of TAS-120 and TAS-120 + fulvestrant in patients with locally advanced/metastatic breast cancer harboring FGFR gene amplifications.

Objective

Primary Objectives: The primary objective of this study is to assess the antitumor activity of TAS-120 as monotherapy or in combination with fulvestrant in the treatment of patients with metastatic breast cancer harboring FGFR amplifications, as measured by: - ORR in patients with centrally confirmed FGFR2 amplification and measurable disease(Cohorts 1, 2) - Clinical benefit rate (CBR) in patients with centrally confirmed FGFR2 amplification and nonmeasurable, evaluable disease (Cohort 3) - 6-month progression-free survival (PFS) rate in patients with centrally confirmed high level FGFR1 amplification and measurable disease (Cohort 4).

Treatments

Therapies

Medications

Faslodex (fulvestrant); TAS-120 (); fulvestrant ()

Inclusion Criteria

Histologically or cytologically confirmed recurrent locally advanced or metastatic breast cancer not amenable to treatment with curative intent, meeting all of the criteria for 1 of the following cohorts:

A. Cohort 1 i. HR+ HER2- breast cancer harboring an FGFR2 gene amplification. HR+ HER2- breast cancer is defined per the local pathology report as estrogen receptor (ER) >1% and/or progesterone receptor (PR) >1%, HER2-negative per American Society of Clinical Oncology (ASCO) and the College of American Pathologists (CAP) guidelines, 2018.

ii. Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 iii. Has received 1-3 prior endocrine-containing therapies and up to 2 prior chemotherapy regimens for advanced/metastatic disease iv. Has received prior treatment with a CDK4/6 inhibitor or is ineligible for such i. treatment (per Investigator decision) ii. Has experienced disease progression/recurrence within 1 month following the completion of any endocrine therapy for advanced/metastatic breast cancer

B. Cohort 2 i. TNBC harboring an FGFR2 gene amplification. TNBC is defined as negative for ER, PR and HER2. Negative for ER and PR includes the following: local pathology report classifies them as negative, Allred Score of 2 or below or > ii. Measurable disease per RECIST 1.1 iii. Has received at least 1 prior chemotherapy or chemotherapy/immunotherapy iv. (PD-L1/PD-1 inhibitors) regimen for advanced/metastatic disease Has experienced disease progression/recurrence during or after the most recent prior chemotherapy for advanced/metastatic breast cancer

C. Cohort 3 i. TNBC or HR+ HER2- breast cancer (defined as above) harboring an FGFR2 gene amplification ii. Non measurable, evaluable disease per RECIST 1.1. Patients with bone-only disease must have lytic or mixed lytic-blastic lesions iii. Other criteria for either HR+ HER2- breast cancer or TNBC should be met as described for Cohort 1 and 2, respectively

D. Cohort 4 i. HR+ HER2- breast cancer (defined as above) harboring an FGFR1 high-level gene amplification ii. Measurable disease per RECIST 1.1 iii. Has received 1-2 prior endocrine-containing therapies and no more than 1 prior chemotherapy regimen for advanced/metastatic disease. Prior treatment with fulvestrant is not permitted.

iv. Has received prior treatment with a CDK4/6 inhibitor or is ineligible for such i. treatment (per Investigator decision) ii. Pre/peri-menopausal patients must be on goserelin. Patients must have commenced treatment with goserelin or an alternative GnRH agonist at least 4 weeks prior to the first dose of fulvestrant. If patients have received an alternative GnRH agonist prior to study entry, they must switch to goserelin for the duration of the trial. Postmenopausal is defined as at least one of the following criteria: age ≥60 years; age > iii. Has experienced disease progression/recurrence within 1 month following the completion of any endocrine therapy for advanced/metastatic breast cancer.

Archival or (preferably) fresh tumor tissue must be available for central laboratory confirmation of FGFR amplification.

Has adequate organ function as defined by protocol

Exclusion Criteria

History and/or current evidence of any of the following disorders:

Non-tumor related alteration of the calcium-phosphorus homeostasis that is considered clinically significant in the opinion of the Investigator

Ectopic mineralization/calcification, including but not limited to soft tissue, kidneys, intestine, or myocardia and lung, considered clinically significant in the opinion of the Investigator

Retinal or corneal disorder confirmed by retinal/corneal examination and considered clinically significant in the opinion of the Investigator.

Corrected QT interval using Fridericia's formula (QTcF) >470 msec. Patients with an atrioventricular pacemaker or other condition (for example, right bundle branch block) that renders the QT measurement invalid are an exception and the criterion does not apply.

Treatment with any of the following within the specified time frame prior to the first dose of TAS-120:

Major surgery within 4 weeks (the surgical incision should be fully healed)

Radiotherapy for extended field within 4 weeks or limited field radiotherapy within 2 weeks

Any prior systemic therapy regardless of the stop date, but the patient must have recovered to eligibility levels from prior toxicity

Any investigational agent received within 30 days or 5 half-lives (whichever is shorter)

Prior treatment with an FGFR inhibitor

Cohort 4 only: Prior treatment with fulvestrant, or known hypersensitivity to fulvestrant.

A serious illness or medical condition(s) including but not limited to the following: Known acute systemic infection; Myocardial infarction, severe/unstable angina, or symptomatic congestive heart failure within the previous 6 months; History or current evidence of serious uncontrolled ventricular arrhythmia; Chronic diarrhea diseases considered to be clinically significant in the opinion of the Investigator; Congenital long QT syndrome, or any known history of torsade de pointes, or family history of unexplained sudden death; Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or TAS-120 administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study

Brain metastases that are untreated or clinically or radiologically unstable (that is, have been stable for > History of another primary malignancy that is currently clinically significant or currently requires active intervention

Pregnant or lactating female

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.